Atossa Therapeutics Joins ARDD 2026 Clinical Trials Panel
Seattle, Washington, U.S., September 24, 2026 Atossa Therapeutics Inc. announced that its Chief Executive Officer and Founder, Dr. Steven...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Seattle, Washington, U.S., September 24, 2026 Atossa Therapeutics Inc. announced that its Chief Executive Officer and Founder, Dr. Steven...
Minneapolis, Minnesota, U.S., September 24, 2026 Marani Health has received U.S. Food and Drug Administration (FDA) 510(k) clearance for...
